Ocuphire Pharma Q2 EPS $(0.30) Misses $(0.24) Estimate, Sales $1.11M Miss $2.61M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma (NASDAQ:OCUP) reported Q2 earnings per share (EPS) of $(0.30), missing the analyst consensus estimate of $(0.24) by 25%. The company also reported quarterly sales of $1.11 million, which missed the estimate of $2.61 million by 57.39%. Both EPS and sales figures represent significant declines compared to the same period last year.
August 13, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocuphire Pharma reported Q2 EPS of $(0.30), missing estimates by 25%, and sales of $1.11M, missing estimates by 57.39%. Both figures show significant declines compared to the same period last year.
The significant misses in both EPS and sales, along with the year-over-year declines, are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100